July 24, 2025 7:50am

I’ll be stalking the upside in next few sessions, grab the highs …

As econs and sector earnings season approach, the sand of share pricing will be draining from this hourglass; the clearer we should see to what to do 

Pre-open Signals: are fluctuating

 

BREAKING: Initial claims for state unemployment benefits fell by 4,000 to a total of 217,000 in the week that ended July 19. That’s the 6th straight weekly decline and claims are now at their lowest level since mid-April. The number of people already collecting unemployment benefits in the week of July 12 inched up by 4,000 to 1.96 M. These so-called continuing claims had surged but have been relatively steady in recent weeks. Still, they are a sign that it is getting harder for job seekers to find new positions after being let go from prior jobs. The 4-week average of jobless claims fell 5,000 to 224,500. That’s also the lowest since April.

Never leave an investor uninformed … I try to rationalize the whys of inclines or declines in share pricing as lately it seems no news is good news

I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Let’s get to the point, few adverbs and even fewer adjectives, no vacillating; I get right to the point, telling investors what has meaning and why news or indications matter.

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: Show me the money, as the sector upside slurps … https://www.regmedinvestors.com/articles/14010

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Thursday: The pre-open Dow futures are DOWN -0.36% or (-165 points), the S&P futures are UP +0.12% or (+8 points) and the Nasdaq futures are UP +0.35% or (+81 point)

  • Futures are mixed and barely fluctuating, Thursday, 7/24
  • European markets rose and stayed positive,
  • Asia-Pacific markets traded mostly higher, yet slipped mixed at the close

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed UP +507.85 points or +1.14%, the S&P closed UP +49.33 points or +0.78% while the Nasdaq closed UP +127.33 points or +0.61%
  • Tuesday: The Dow closed UP +179.37 points or +0.40%, the S&P closed UP +4.02 points or +0.06% while the Nasdaq closed DOWN – 81.49 points or -0.39%
  • Monday: The Dow closed DOWN -19.12 points or -0.04%, the S&P closed UP +8.81 points or +0.14% while the Nasdaq closed UP +78.52 points or +0.38%

Economic Data Docket: Initial jobless claims, S&P flash U.S. services PMI, S&P flash U.S. manufacturing PMI and New home sales

 

Q3 – July – 1 market holiday, 11 positive and 4 negative closes

Q2  

  • June – 1 market holiday, 1 neutral, 8 negative, and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I’ll pass; a flap is coming, it is still a mix of more econs, tariffs developments, ups, downs and just plain uncertainty

 

The BOTTOM LINE: I … STILL …feel RED flags are flying and the firing range is open!

July is slowly coming to an end with 7 sessions left.

  • After econs stifled the sector and markets, and summer doldrums, tariff conflicts, vacations and selling before the earnings cycle to pay for the lobster rolls.

 

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS), Moderna (MRNA) and 8/5, Tuesday = AxoGen (AXGN)

 

Cell and gene therapy sector equities closed Wednesday, Tuesday and Monday positive ,,,

  • After Friday’s negative after positive Thursday and Wednesday continued the run to the upside after Tuesday positive close after diving on Monday
  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

To characterize July, to understand the “flow” of markets, the cell and gene therapy sector and economic karma…

  • 7/23 – Wednesday closed positive with 30 positive, 1 negative and 4 flats
  • 7/22 – Tuesday closed positive with 19 positive, 10 negative and 6 flats
  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 - Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

Maybe a day late, but a $10 dollar gain:

With the threat of tariffs looming for medicines imported to the U.S., AstraZeneca has unveiled a plan to invest $50 billion in the country by 2030.  AZ’s commitment matches a $50 billion plan in the U.S. revealed by Roche in April.  In March, Johnson & Johnson unveiled a $55 billion U.S. pledge, which includes bolstering its MedTech business.  Eli Lilly, Sanofi and Novartis. Each of these companies has committed to spend at least $20 billion to bolster its facilities in the U.S. by the end of the decade.

  • The centerpiece of AZ’s effort is a drug substance manufacturing facility—the highest-priced plant in company history—that will be located at a yet-to-be-determined site in Virginia.
  • The massive investment is part of a push by the company to generate $80 billion in sales by the end of the decade, with 50% of the haul coming in the United States. Last year, the British/Swedish company reported revenue of $54 billion, with U.S. sales accounting for 42% of the figure.
  • The spending plan is on top of a $3.5 billion capital investment the company revealed in November of last year, days after the election of President Donald Trump.
  • In addition to establishing the Virginia site, AZ plans to use the U.S. outlay to expand its R&D facilities in Gaithersburg, Maryland, and Cambridge, Massachusetts.
  • AZ also will increase the capability of its gene therapy production facilities in Rockville, Maryland, and Tarzana, California, as well as its plants in Mount Vernon, Indiana, and Coppell, Texas. It also plans to open new sites to supply clinical trials, it said.
  • The company has several promising candidates in the clinic, including an oral GLP-1 obesity drug, a PCSK9 inhibitor which has shown potential to reduce cholesterol and baxdrostat, a treatment for hypertension and potentially other indications that recently excelled in a P3 study. <Fierce Biotech>

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, I brace myself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.